Recombinant Human Papillomavirus Nonavalent Vaccine

BIOLOGICAL10 trials

Sponsors

National Cancer Institute (NCI), M.D. Anderson Cancer Center, Fred Hutchinson Cancer Center, AIDS Malignancy Consortium

Conditions

AIDS-Related Human Papillomavirus InfectionAllogeneic Hematopoietic Stem Cell Transplant RecipientHIV InfectionHematopoietic and Lymphoid Cell NeoplasmHigh Grade Anal Canal Intraepithelial NeoplasiaHigh Grade Cervical Squamous Intraepithelial NeoplasiaHigh Grade Vulvar Squamous Intraepithelial LesionHuman Papillomavirus Infection

Phase 1

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

RecruitingNCT05985681

National Cancer Institute (NCI)Human Papillomavirus-Related Carcinoma

Start: 2026-01-27End: 2028-08-01Target: 18Updated: 2026-09-09

Phase 2

Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants

Active, not recruitingNCT02568566

National Cancer Institute (NCI)Human Papillomavirus-Related Carcinoma

Start: 2016-05-19End: 2027-01-10Updated: 2026-07-10

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

Active, not recruitingNCT03036930

National Cancer Institute (NCI)Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma

Start: 2017-06-23End: 2027-03-10Updated: 2026-05-29

Phase 3

HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV

CompletedNCT03284866

AIDS Malignancy ConsortiumAIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia, HIV Infection

Start: 2019-07-31End: 2025-08-05Updated: 2026-01-28

Phase 4

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Active, not recruitingNCT03023631

M.D. Anderson Cancer CenterAllogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm

Start: 2017-04-23End: 2026-09-30Updated: 2026-07-16

HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

TerminatedNCT03051516

Fred Hutchinson Cancer CenterHigh Grade Anal Canal Intraepithelial Neoplasia, High Grade Vulvar Squamous Intraepithelial Lesion

Start: 2017-08-01End: 2022-12-31Updated: 2024-02-28

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study

Active, not recruitingNCT03180034

National Cancer Institute (NCI)Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma

Start: 2017-11-29End: 2028-08-01Updated: 2025-09-04

Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial

CompletedNCT04265950

Fred Hutchinson Cancer CenterHIV Infection

Start: 2022-03-10End: 2026-06-11Updated: 2026-07-02

Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial

Active, not recruitingNCT05237947

National Cancer Institute (NCI)Human Papillomavirus-Related Cervical Carcinoma

Start: 2022-03-01End: 2026-12-31Target: 5000Updated: 2026-06-30

ESCUDDO Long Term Follow Up

Enrolling by invitationNCT07706673

National Cancer Institute (NCI)Human Papillomavirus Infection, Human Papillomavirus-Related Malignant Neoplasm

Start: 2026-08-11End: 2031-01-15Target: 13700Updated: 2026-09-01

Related Papers

Noninferiority of One HPV Vaccine Dose to Two Doses.

2025-12-031 citations

ULACNet-301, OPTIMO protocol: optimizing HPV vaccination regimen for cancer prevention in children and adolescents living with HIV.

2025-01-27

Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial

Vaccine2021-11-2937 citations

Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial.

2021-09-2737 citations

Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15-25 years: A phase IV randomized comparative study.

2020-05-2510 citations

Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA)

JAMA Network Open2019-04-1230 citations

A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-11 year-old girls and boys - clinical protocol.

2019-04-018 citations